Principal Investigator
David Walling, MD
Collaborative Neuroscience Research
- 3 trials
- 1 compound
Therapeutic focus
- Schizophrenia
- Alzheimer Disease
- Bipolar Disorder
All trials (3)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT06442462 | Phase 2 | Active | Tazbentetol | Spinogenix, Inc. |
| NCT04920786 | Phase 1 | Completed | — | TrueBinding, Inc. |
| NCT01948024 | Phase 1 | Completed | — | Sun Pharmaceutical Industries Limited |
Compounds studied
Trial sites (10)
- Long Beach, California, United States
- Leesburg, Florida, United States
- Costa Mesa, California, United States
- Garden Grove, California, United States
- Box Hill, Victoria, Australia
- Atlanta, Georgia, United States
- Melbourne, Victoria, Australia
- Little Rock, Arkansas, United States
- Miami, Florida, United States
- Charlotte, North Carolina, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).